Asset Details
Do you wish to reserve the book?
Evinacumab in Patients with Refractory Hypercholesterolemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evinacumab in Patients with Refractory Hypercholesterolemia
Do you wish to request the book?
Evinacumab in Patients with Refractory Hypercholesterolemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evinacumab in Patients with Refractory Hypercholesterolemia
2020
Overview
Angiopoietin-like 3 is an inhibitor of lipoprotein lipase. Evinacumab is a monoclonal antibody that inhibits angiopoietin-like 3, activating lipoprotein lipase. In patients with hypercholesterolemia that is refractory to statin and PCSK9 inhibitor therapy, the use of evinacumab reduced plasma lipid levels by more than 50% at the maximum dose.
Publisher
Massachusetts Medical Society
Subject
/ Angiopoietin-like Proteins - antagonists & inhibitors
/ Antibodies, Monoclonal - administration & dosage
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized - administration & dosage
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Anticholesteremic Agents - administration & dosage
/ Anticholesteremic Agents - adverse effects
/ Anticholesteremic Agents - therapeutic use
/ Drug Administration Schedule
/ Female
/ Humans
/ Hyperlipoproteinemia Type II - drug therapy
/ Lipids
/ Male
/ Mutation
/ Statins
